Ourobio was founded by Alec Brewer, Kobe Rogers in 2020.

Who are Ourobio's investors?

Ourobio's investors include Lighthouse Network Ventures Llc.

Where is Ourobio headquartered?

Ourobio is headquartered in Indianapolis, US.

Ourobio

Indianapolis, US · Founded 2020 · 2 employees on LinkedIn · 1 known investors

Find your way into Ourobio

129 people in our graph share verified history with the Ourobio team — schools, employers, funds. One of them is your warm intro.

Bryson Hearneunlockedknows Alec Brewer · together at University of Virginia (overlapped)

×7knows the team · via University of Virginia

knows the team · via iGEM Competition

×3knows the team · via Chaminade High School

Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.

Biotech Circular Economy Cleantech New Materials

Founders & leadership

Ourobio was founded in 2020 by Alec Brewer and Kobe Rogers.

Alec Brewer inFounder & Chief Executive OfficerAlec Brewer is founder and CEO of Ourobio, which develops engineered microorganisms to convert industrial byproducts into sustainable biomaterials using synthetic biology.

Kobe Rogers inFounder & Chief Operations OfficerKobe Rogers has experience in laboratory operations, R&D, and computational and molecular biology. He has led research teams, managed grants and secured non-dilutive funding, and contributed to process optimization and compliance frameworks in biotech.

Investors · 1

Lighthouse Network Ventures LlcRichmond

Competitors · 2

by search overlap

Ouro Medicines4 shared keywordsOuro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions. It is advancing a pipeline of biologics and small molecules across immunology and related therapeutic areas.

Surf3 shared keywordsSurf Bio is a preclinical biopharmaceutical company developing its SnapShot technology, which uses a proprietary polymer to create ultra-high-concentration antibody and biologic formulations (600+ mg/mL, doses over 1,000 mg) for delivery via a standard autoinjector. The technology enables at-home subcutaneous self-injection of monoclonal antibodies and biologics as an alternative to in-clinic IV infusion, and is offered to pharmaceutical API manufacturers through partnerships.

Companies competing with Ourobio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
Environmental Protection Agency (EPA)	Phase I	2023	$100K
Environmental Protection Agency (EPA)	Phase I	2021	$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Ourobio do?: Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.
Who founded Ourobio?: Ourobio was founded by Alec Brewer, Kobe Rogers in 2020.
Who are Ourobio's investors?: Ourobio's investors include Lighthouse Network Ventures Llc.
Where is Ourobio headquartered?: Ourobio is headquartered in Indianapolis, US.